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Endocrine disruptionWhether thresholds exist for endocrine active substances and for endocrine disrupting effects of exoge-
nous chemicals has been posed as a question for regulatory policy by the European Union. This question
arises from a concern that the endocrine system is too complex to allow estimations of safe levels of
exposure to any chemical with potential endocrine activity, and a belief that any such chemical can aug-
ment, retard, or disrupt the normal background activity of endogenous hormones. However, vital signal-
ing functions of the endocrine system require it to continuously discriminate the biological information
conveyed by potent endogenous hormones from a more concentrated background of structurally similar,
endogenous molecules with low hormonal potential. This obligatory ability to discriminate important
hormonal signals from background noise can be used to deﬁne thresholds for induction of hormonal
effects, without which normal physiological functions would be impossible. From such thresholds, safe
levels of exposure can be estimated. This brief review highlights how the fundamental principles govern-
ing hormonal effects – afﬁnity, efﬁcacy, potency, and mass action – dictate the existence of thresholds
and why these principles also deﬁne the potential that exogenous chemicals might have to interfere with
normal endocrine functioning.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
The European Commission asked DG Environment to develop a
deﬁnition of and criteria for identiﬁcation of endocrine disrupting
chemicals (EDCs) applicable to several legislative structures, e.g.,
the plant protection products regulation (Reg. (EC) No 1107/
2009), the biocidal products regulation (Reg. (EC) No 528/2012),
and REACH (Reg. (EC) 1907/2006. Besides deﬁnitions and criteria
for EDCs, the Commission intends to answer whether EDC thresh-
old levels can be determined. Stakeholders offer different opinions
on this matter and several agencies have responded to these issues.
The European Food Safety Authority (EFSA) recommended clariﬁ-
cation of issues regarding biological thresholds and the criteria
for adversity versus physiological modulation and homeostatic re-
sponses (EFSA, 2013). The Swedish Chemicals Agency concluded
‘‘. . .that the decision on whether or not to accept a non-threshold
model for EDCs has to be based on considerations of mechanism
of action. Thus, the assumption of no threshold may be as valid,
or questionable, for EDCs as for genotoxic carcinogens.’’ (KemI,2013a). The UNEP and WHO (2013) report entitled ‘‘State of Sci-
ence of Endocrine Disrupting Chemicals’’ concluded that endocrine
disruptors produce non-linear dose responses (there referring to
non-monotonic dose response curves) and no threshold can be as-
sumed. Similarly, several publications cited in these reports ques-
tion the existence of thresholds and suggest that no safe dose can
be deﬁned for EDCs.
Overall, six primary considerations have been offered to refute
safe threshold levels for EDCs (KemI, 2013b): (1) the complexity
of the endocrine system; (2) the presence of sensitive developmen-
tal stages; (3) long intervals between the exposure event and the
appearance of the adverse effect; (4) no threshold of effect for an
endocrine disrupting agent added to a hormone system that is al-
ready active, where theoretically, one molecule could activate a
receptor when adding to background; (5) scientiﬁc difﬁculties that
preclude establishing safe exposure levels, especially for human
and other populations, and; (6) the scientiﬁc uncertainty in pre-
dicting endocrine effects and thereby assessing risks of EDCs.
Many of these considerations can be addressed through an
understanding of how the normal functioning of the endocrine
system relies on fundamental principles of receptor, enzyme,
and transport kinetics, upon which the ﬁelds of endocrine physi-
ology and pharmacology are built. The fundamental principles of
endocrine action dictate the existence of thresholds that deter-
mine whether and to what degree any substance – endogenous
or exogenous – may affect the endocrine system. Hence, this
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could not function if thresholds did not exist; (2) how principles
of endocrine pharmacology – afﬁnity, efﬁcacy and potency based
on mass action (for reviews of receptor, enzyme and transport
kinetics, see Matthews, 1993; Kenakin, 2009) – dictate thresholds,
and; (3) why all conceivable effects of chemicals acting through
or interfering with aspects of endocrine mechanisms that rely
on molecular speciﬁcity are governed by these basic rules. In
short, as has been concluded for other modes of action (MOA),
we assert that principles of endocrine pharmacology imply cer-
tain ‘‘. . ..rate-limiting key events that, if not met, can lead to a
threshold for the dose–response, irrespective of the MOA in-
volved.’’ (Boobis et al., 2009).
We attempt here to concisely describe the fundamental prin-
ciples that make the case for the existence of thresholds in
endocrine action, but we speciﬁcally do not represent this work
as a critical treatment of all related issues or as a comprehensive
review of endocrine action. Toward this end, we have cited gen-
eral textbooks in several places, for two important reasons. First,
some concepts would have required intricate explanations if
pieced together from the primary literature that established
them, thus reducing clarity and brevity. Second, we wish to
emphasize that many principles discussed here are sufﬁciently
well established in the ﬁeld of endocrine pharmacology that they
have been taught in standard textbooks for many years up to the
present. Finally, although we make the case that thresholds are
obligate for endocrine action, we do not attempt to deﬁne
thresholds for adverse effects, which may be higher than the
thresholds at which normal endocrine functioning can be af-
fected due to ADME and other adaptive and protective mecha-
nisms within animals.
2. Elementary review of endocrine pharmacology
The endocrine system provides major physiological controls in
animals with critical roles in development, maturation, and main-
tenance of health through long-term homeostasis. These func-
tions are accomplished through sophisticated chemical signals
mediated by substances known as hormones, which are produced
in and released from speciﬁc cells and transported, often via
blood, to target organs or tissues where the hormonal response
is produced (Chedrese, 2009). Many different types of hormonal
signals are required for the complex functioning of higher mam-
mals and more than ﬁve hundred different effector molecules
have been identiﬁed in humans (Chedrese and Celuch, 2009).
Hormones within related classes are usually derived from com-
mon precursors and share similar chemical structures, e.g., ste-
roid hormones derived from cholesterol or catecholamine
hormones derived from tyrosine (Chedrese, 2009). Structural sim-
ilarities extend to many common endogenous molecules, includ-
ing hormone precursors and metabolites and intermediates and
end-products of various biochemical pathways (Chedrese and Ce-
luch, 2009).
Typical extracellular concentrations of functionally active hor-
mones are in the range of 1011 to 109 molar whereas those of
structurally similar, non-hormone molecules (e.g., sterols, amino
acids, peptides) are in the range of 105 to 103 molar (Chedrese
and Celuch, 2009; Grannar, 1993). Given this overwhelming pres-
ence of structurally similar molecules relative to hormones, the
challenge to maintaining a functional and efﬁcient hormone-based
communication system is formidable. Normal endocrine function-
ing requires that target cells efﬁciently identify and differentiate
the various hormones from other molecules that are present in
the extracellular ﬂuid at molar excesses of 106- to 109- times
(Chedrese and Celuch, 2009; Grannar, 1993). Without the abilityto clearly distinguish molecules that convey critical physiological
information from structurally similar molecules in the body, the
endocrine system would be unable to process speciﬁc, vital signals
amidst a steady roar of biological noise.
The capacity to achieve these distinctions is based on conforma-
tional matching of hormones with receptor structures present in
target tissues (Chedrese and Celuch, 2009). These matches are
highly selective so that only tight structural pairings produce bio-
logical effects that convey important information (Chedrese, 2009;
Chedrese and Celuch, 2009). Only certain hormones (called ‘‘li-
gands’’) ﬁt a particular class of hormone receptors with sufﬁcient
complementarity to produce receptor-mediated effects (Chedrese
and Celuch, 2009).
2.1. Afﬁnity
Afﬁnity is a primary molecular property enabling the endocrine
system to communicate vital information to different tissues of the
body and to distinguish this information from biological noise. In
broad terms, afﬁnity is the strength of the molecular interaction
between a receptor and its ligand (Chedrese and Celuch, 2009;
Matthews, 1993), conferring a tendency for the molecules to re-
main associated once contact has occurred. An endogenous hor-
mone has high afﬁnity for its conjugate receptor such that when
contact occurs, a strong molecular interaction follows. Conversely,
molecules with low afﬁnity for a hormone receptor will not associ-
ate tightly and will more readily dissociate from it.
Afﬁnity has two important consequences for hormone action. A
high-afﬁnity ligand ﬁts the receptor well, such that any given con-
tact event is likely to result in a conformationally correct associa-
tion. This accomplishes the ﬁrst step of hormone action at the
target cell, called receptor binding. Second, for a given number of
molecular contact events, a high afﬁnity ligand has a much greater
tendency to remain associated with its receptor than a low afﬁnity
ligand, a property typically quantiﬁed by a dissociation constant.
The afﬁnity of a ligand for its receptor determines the fraction of
available receptors that will be occupied at any particular ligand
concentration (Chedrese and Celuch, 2009; Matthews, 1993), usu-
ally referred to as ‘‘receptor occupancy.’’ Thus, the greater the afﬁn-
ity, the lower the concentration of the ligand required to bind and
occupy receptors.
The afﬁnities of various hormone receptor-ligand combinations
can vary depending on the needs of the particular hormonal path-
way. Normally, afﬁnities are ﬁnely matched with the concentration
of hormones required to produce the desired response in target
cells (Chedrese and Celuch, 2009). As well, the fraction of available
receptors that must be activated to produce a cellular response
varies with target cell and tissue type. Overall, afﬁnity dictates
whether the ligand has the opportunity to accomplish the second
task of hormone action, receptor activation (Chedrese and Celuch,
2009; Matthews, 1993).
2.2. Efﬁcacy
The degree of receptor binding and occupation achieved by low
concentrations of high afﬁnity endogenous hormone ligands could
theoretically be augmented by a proportionately greater concen-
tration of low afﬁnity ligands, and thus, might lead to cellular re-
sponses. However, afﬁnity is not the only determinant of how
effectively a ligand activates a receptor. The ability of a bound li-
gand to efﬁciently activate a receptor and trigger a cellular re-
sponse is called ‘‘efﬁcacy.’’ There are several theories on the
molecular nature of efﬁcacy, including receptor occupancy theory
and conformational models, with contributions from post-receptor
events (Clarke and Bond, 1998; Kenakin, 2004). Efﬁcacy can range
C.J. Borgert et al. / Regulatory Toxicology and Pharmacology 67 (2013) 83–88 85from negative to positive values where a ligand with high (posi-
tive) efﬁcacy is capable of eliciting the maximal cellular response.1
2.3. Potency
Together, afﬁnity and efﬁcacy determine the potency of a ligand
to activate speciﬁc hormone receptors and to elicit speciﬁc cellular
responses in target tissues. Because the manifestation of these
properties involves a variety of molecular interactions, potency
and efﬁcacy may not be tightly coupled across dose–response
ranges and among different tissues and hormone receptor types
(Kenakin, 2009; Simons, 2008). However, both properties are
essential for hormonal activity (Kenakin, 2009), and endogenous
hormones tend to be very potent because they typically possess
both high afﬁnity and high efﬁcacy. Pharmacologically, these are
referred to as potent hormone receptor agonists. Molecules with
high afﬁnity but no efﬁcacy are receptor antagonists, i.e., they
block the action of endogenous hormones because they interact
with and occupy the receptor, preventing its occupation by ligands
with efﬁcacy, but themselves produce no response.
Endogenous hormones have high potency and so produce a
greater cellular response for a given concentration than lower po-
tency ligands. For example, in a yeast reporter assay, the endoge-
nous estrogen 17b-estradiol achieves one-third maximal
activation of the native human estrogen receptor at a concentra-
tion of 1010 molar and maximal activation at 108 molar. In con-
trast, testosterone produces no measurable activation of that
receptor at concentrations less than 106 molar, and its highest
achievable activation requires 105 molar but is only one-third
maximal. Progesterone is inactive at all concentrations in this sys-
tem (Chen et al., 2004). On the basis of this assay, testosterone
exhibits a relative potency of about 1  105 (one one-hundred
thousandth) that of 17b-estradiol.
A chemical with low afﬁnity can produce a cellular response if it
has efﬁcacy and if a sufﬁcient concentration can be achieved at the
receptor site. However, at relatively low concentrations, such
chemicals would lack detectable endocrine activity against the
background of endogenous hormones already occupying receptors.
For instance, even in the treatment of hormone-deﬁciency disor-
ders, where the background concentrations of natural hormone
are low, only potent molecules have been found to be effective
therapeutically. Similarly, during a woman’s lifetime, potency dif-
ferences dictate which estrogenic hormone is dominant – 17b-
estradiol > estrone > estriol – yet even these differences span less
than two orders of magnitude (Chen et al., 2004; Kuiper et al.,
1997). In contrast, putative environmental estrogens exhibit
potencies three or more orders of magnitude below that of 17b-
estradiol (Borgert et al., 2003; Wu et al., 2008), indicating a low po-
tential for estrogenic activity. Since circulating endogenous estro-
gen concentrations are several hundred times greater in women
compared to rodent test species, an inference of human risk from
low-potency chemicals based on endocrine disruptive effects ob-
served in those species would be speculative (Witorsch, 2002).
2.3.1. Thresholds
The differences in afﬁnity and efﬁcacy between hormones and
structurally similar endogenous molecules that do not act as hor-
mones imply potency thresholds in the activation of cellular re-
sponses (Borgert et al., 2012). Although such biological
thresholds would vary for different types of hormone receptors
and with the degree of receptor activation required to induce cel-1 Efﬁcacy is technically considered a product of a ligand’s ability to stimulate a
receptor, termed ‘‘intrinsic activity,’’ and the ability of the stimulated receptor to elicit
the cellular response. The distinction is not essential for understanding hormone
action and thresholds.lular responses, any detectable hormonal activity will require an
appropriate concentration of ligand with sufﬁcient potency. These
sufﬁciency requirements amount to thresholds for activation. Tar-
get cells may have receptors for various hormones, each present in
a ﬁnite number at any given time (Chedrese and Celuch, 2009).
However, target cells do not respond to receptor activation on an
individual basis, but read the status of receptor activation collec-
tively. An example of this is the regulation of gene expression,
where on average, at least 5 transactivators need to be activated
simultaneously to induce gene expression for any gene. Many, if
not most, of these transactivator activations are the result of activ-
ity in the endocrine system (Nelson and Cox, 2008). Thus, hor-
monal responses in target organs, tissues or groups of cells
require coordinated changes in the status of receptor activation.
This requirement for a coordinated change in receptor activation
creates a second threshold mechanism by which the endocrine sys-
tem distinguishes important signals from biological noise (Mat-
thews, 1993).
Nonetheless, it would be fair to ask, can the thresholds of bio-
logical potency and for a coordinated change in receptor activation
status in target tissues and organs could be overcome by a molar
excess of molecules that have low afﬁnity but high efﬁcacy, partic-
ularly if the endogenous hormone concentration is augmented by
continuous, long-term exposure to environmental chemicals with
similar properties? Some assert that because the endocrine system
is already stimulated by endogenous hormones, the threshold for
activation is already exceeded and therefore, any potential hor-
monal activity that is introduced, no matter how slight, will in-
crease (or decrease) this baseline activity. This is the
foundational hypothesis of the endocrine disruptor theory – usu-
ally termed ‘‘additivity to background’’ – and asserts that because
concentrations of endogenous hormones are low and ﬂuctuate
widely, small additions or subtractions of even a single molecule
will result in altered hormonal responses (Hass et al., 2013). A
few simple calculations, however, illustrate why one or a few mol-
ecules added to an existing level of molecules will not change
receptor occupancy in any detectable way, and why the molar ex-
cess of low potency ligands would need to be substantial to alter
hormonal responses.
If the endogenous hormone is present at 10 parts per quadril-
lion, and we assume it has a molecular weight of 100 mass units,
its concentration is 1  1013 molar, or 6  1010 molecules per li-
ter. This is at the low end of the effective physiologic concentration
range for even the most potent endogenous hormones. The diam-
eter of typical eukaryotic cells ranges from 10 to 100 lm. Choosing
a value near the center of this range gives a radius of 20 lm, and
assuming the cell is roughly spherical gives a volume for a single
cell of about 3  1011 liters, which translates to about 2 molecules
per cell. At 1  1013 molar, a hormone with an afﬁnity constant of
1  1011 molar would produce only about 1% receptor occupancy.
If the endogenous hormone is present at its KD concentration
(1  1011 molar) receptor occupancy would be at 50%. Adding
an equipotent ligand at a concentration of 1  1013 molar would
increase receptor occupancy to 50.25%. If we add a ligand with high
efﬁcacy but with an afﬁnity 103 lower than the endogenous ligand,
it would require 250 times more of that molecule (2.5  1011 -
molar) to increase receptor occupancy by the same amount. If in-
stead we add a ligand with the same afﬁnity as the endogenous
hormone but with low efﬁcacy at a concentration of 1  1013 -
molar, this molecule would behave as a competitive antagonist
and it would decrease receptor occupancy by the endogenous hor-
mone by 0.25%. Similarly, lower concentrations of added ligands
would have proportionally smaller effects. Therefore, any added
receptor ligand, endogenous or exogenous, highly potent or not,
would need to approach at least the 1  1013 molar level to have
any measurable or detectable inﬂuence on receptor occupancy.
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molecules in the body water compartment (about 33 liters) of an
average sized woman (66 kg), and more in men, in whom body
water is typically a higher percentage of the body weight. This dis-
putes the no threshold effect level hypothesis, given that a receptor
is necessary for the effect, and negates the notion that a single mol-
ecule could produce an effect, even theoretically. If this were not
so, normal, small changes in the intra- or extracellular milieu –
i.e., in the concentrations of hormone precursors, metabolites, met-
abolic intermediates, etc., many of which possess low afﬁnity and
low efﬁcacy for hormone receptors – would be detected as hor-
monal signals and produce measurable tissue and organ
disturbances.
An example of this phenomenon involves the demonstrated
ability of essential fatty acids to stimulate proliferation (Rose and
Connolly, 1989) and selectively modulate estrogenic responses
(Menendez et al., 2004) in estrogen-sensitive human breast cancer
cells in culture, and to bind estrogen receptors and induce certain
estrogen responsive genes in other in vitro assays (Liu et al., 2004).
Nonetheless in women administered ﬂaxseed supplementation, a
rich source of these essential fatty acids, no signiﬁcant changes
are seen in serum hormones or biochemical markers of bone
metabolism, both of which would be expected from estrogenic ac-
tion (Brooks et al., 2004). Flaxseed supplementation does not alter
follicle stimulating hormone or estradiol levels or produce clini-
cally important estrogenic effects on the vaginal epithelium or
endometrium in women (Colli et al., 2012), or alter uterine re-
sponses to estradiol in rats (Sacco et al., 2012). Insufﬁcient potency
appears to underlie the inability of even high levels of essential
fatty acids to exhibit hormonal effects, despite activity in vitro. An-
other recently published example of this principle shows that
metabolites of dehydroepiandrosterone (DHEA) lack sufﬁcient po-
tency via androgen or estrogen receptors to account for their bio-
logical activities, even though their potencies are within roughly
three orders of magnitude of the principal endogenous hormones
(Shaak et al., 2013). Although neither example precludes all possi-
ble modes of endocrine action, they clearly illustrate the difﬁculty
of reconciling the additivity to background hypothesis with the
ability of hormones to convey meaningful biological information
amidst the high background of endogenous biological noise due
to structurally related endogenous molecules.
Based on the above considerations, in order for an exogenous
chemical substance to be able to alter the normal physiological
functioning of the endogenous endocrine system, it is necessary
for that chemical to achieve a sufﬁcient activity level. This activity
level will depend upon the ability of the chemical substance to
interact with and modify the activity of one or more components
of the endogenous endocrine system, its afﬁnity for such interac-
tions, and its concentration. To be sure, the existence of thresholds
for endocrine activity is demonstrable from theory based on estab-
lished principles of hormone action, as we have argued. The quan-
titative magnitude of a particular threshold is both calculable from
theory, as our earlier example indicates, and empirically estimable.
The minimum level of endocrine activity capable of altering phys-
iological functioning can be used to quantify a biological potency
threshold, the range of which is estimable from empirical measure-
ments relevant to any speciﬁc endocrine activity. Recognizing that
no biological measurement is without technical limitations and
some uncertainty, conservative thresholds could be estimated
based on the life stage or condition at which the activity level of
the primary endogenous ligand is lowest. Deﬁning endocrine
thresholds in this manner identiﬁes the types of endpoints useful
for interpreting biologically meaningful effects, i.e., those that al-
low measurement of relative potency for a speciﬁc hormonal ef-
fect. We have not attempted to deﬁne thresholds for adverse
effects, which may be higher than the thresholds at which normalendocrine functioning may be affected, i.e., biological potency
thresholds, due to ADME and other adaptive and protective mech-
anisms within animals.2.4. Signal ampliﬁcation, regulation of receptor number and
sensitivity, cross-talk, and feedback
Admittedly, an adequate description of endocrine mechanisms
and responses is more complex than the recognition of thresholds
and laws of mass action (Falkenstein et al., 2000; Björnström and
Sjöberg, 2005). Not only are hormonal signals ﬁltered from back-
ground biological noise by potency differences, but hormonal sig-
nals are ampliﬁed, receptor numbers are up- and down-
regulated, there is cross-talk between different hormonal recep-
tors, and hormones themselves are controlled by negative feed-
back loops (Chedrese, 2009). All of these processes are governed
by the kinetic principles explained above, and may be important
in further differentiating hormonal signals from endogenous and
exogenous biological noise. Hormonal signals are enhanced by
modifying factors within cells, a feature that allows the endocrine
system to efﬁciently convey nuanced biological information
through a single receptor-ligand system (Simons, 2008; Grone-
meyer et al., 2004). The variety and complexity of hormone signal
enhancement is beyond the scope of this simple review, but its sig-
niﬁcance cannot be underestimated; signal modiﬁcation further
differentiates biological information from background noise, mak-
ing the endocrine system even more resilient to spurious interrup-
tion, not more sensitive to it. To provide one brief example, the
inﬂuence of modulatory factors, including coactivators, co-repres-
sors, and other transcriptional modiﬁers may inﬂuence the shape
of the dose–response curve for gene expression and may underlie
apparent differences in agonist EC50 values for inducing different
genes via a single hormone receptor. Interestingly, the same factors
that decrease the EC50 values for agonists usually increase the
amount of partial agonist activity for antagonists, and this inverse
relationship suggests that the two behaviors are tightly coupled
(Simons, 2006). Thus, the dynamic sensitivity of hormone recep-
tors to ligand activation appears to be coordinated in such a way
that potency differentials are maintained, and also therefore, pro-
tection against spurious perturbation. The ability of endocrine sig-
naling to convey these distinctions is critical to survival.3. Other arguments against thresholds
The sensitivity of developmental life stages to endocrine-medi-
ated perturbations is one of the arguments used most often as
proof against endocrine thresholds. While true that hormonal
activity is critical and even vital during development, one must
ask whether an increased sensitivity to the severity of a perturba-
tion equates to a lower threshold for that perturbation. These
would seem to be distinctly different phenomena that should be
distinguished when considering thresholds for endocrine disrupt-
ing effects. Similarly, while there is little disagreement that thresh-
olds for endocrine-mediated adverse effects will vary depending
on many factors, there is little evidence suggesting that the funda-
mental rules governing endocrine function cease to apply or that
endocrine thresholds disappear altogether during certain periods
of life. Indeed, thresholds for reproductive toxicity are the norm
(Piersma et al., 2011). Moreover, it has long been known that,
although oral contraceptives are embryo lethal at one hundred
times the human contraceptive dose, fetuses that survive the expo-
sure are not adversely affected (Prahalada and Hendrickx, 1983).
Indeed, endocrine pharmacotherapy could not be as effective as
it is, regardless of whether natural or synthetic remedies are used,
if effective and safe doses could not be predicted. The rare
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sive post-marketing surveillance would contravene this maxim
only if those adverse events were produced by the primary hor-
monal mechanism targeted by the medication. In contrast,
whereas toxic effects of drugs are dose-related, mechanistically
predictable exaggerations of the desired therapeutic effect, unto-
ward side effects and rare adverse drug reactions occur by some
other mechanism and may or may not be dose-related (Edwards
and Aronson, 2000).
Finally, citing the example of hormone-dependent cancers of
the breast and prostate, the argument is often advanced that since
adverse effects already occur at endogenous hormone levels, any
change, no matter how small, portends additional disease. This
argument depends on the logic that because growth and spread
of these cancers depends on hormonal stimulation, endogenous
hormones are the determinative factor in causing the cancer. How-
ever, that logic runs counter to most common rules of causal argu-
mentation, which require a counterfactual demonstration, and
contravenes current theories of cancer progression.
Current theories regarding the role of hormones in carcinogen-
esis posit that cellular abnormalities in hormone-responsive tis-
sues, caused irrespective of hormonal involvement, produce cells
whose response to hormones becomes increasingly aberrant, and
eventually, neoplastic (Li et al., 1993). For example, the cancer
stem cell theory posits that malignant breast stem cells, present
in early development before estrogen receptors are expressed, play
a key role in breast cancer development (Eden, 2010). These theo-
ries explain several observations, including why many individuals
with similar or greater hormonal exposure fail to develop cancer.
The observed correlation between lifetime estrogen exposure and
breast cancer is logical since aberrant cells dependent on estrogen
would be expected to grow more rapidly in the presence of more
estrogen, or to out-compete normal cells whose replication num-
ber is limited by estrogen exposure.4. Conclusion
The manifestation of a detectable hormonal response at the tis-
sue and physiologic level in humans or animals depends on
whether: (a) a sufﬁcient number of speciﬁc cellular receptors are
occupied by ligand molecules of sufﬁcient speciﬁcity and potency
to induce individual cells to respond to a given hormonal signal
and (b) a sufﬁcient number of cells respond to a given hormonal
solicitation, enough to manifest a detectable physiologic effect at
the tissue or organism level. These fundamental principles are de-
rived directly from established knowledge about hormonal mech-
anisms. Normal functioning of the endocrine system thus requires
precise discernment of ligand potency and amount to enable trans-
mission of vital signals amidst an endogenous background of spu-
rious molecular interactions. This ability to discern deﬁnes the
threshold. Potency differences, laws of mass action, and the basic
design and physiological functions of the endocrine system require
and ensure the presence of thresholds.
Without thresholds, there would be chaos in cellular and tissue
responses under normal physiological conditions, even absent
exogenous EDCs, and there could be no regulated progression of
signals and functions compatible with reproduction, development,
behavior, repair, immunity, and life itself. It thus seems intuitive
that if chemicals are to have a chance to disrupt natural endocrine
signals, their doses/concentrations and potencies ought to be sim-
ilar to or stronger than the natural hormones (Dietrich, 2010; Gold-
en et al., 1998; Marty et al., 2011). This strength of potency and
amount deﬁnes a minimum requirement for inﬂuencing endocrine
activity, which implies that deﬁning either an endocrine hazard or
a potential therapeutic effect requires an evaluation of potency andphysiologically achievable concentrations. These principles have
successfully guided endocrine pharmacology (Cleve et al., 2012),
wherein it is recognized that natural hormones and their speciﬁc
modiﬁers are already present at concentrations that occupy the
available cellular receptors and are well controlled to support nor-
mal physiological functioning. A reasoned assessment of the mech-
anisms of hormone signaling and processing shows that safe levels
of exposure can be set for endocrine active substances based on
biological and pharmaceutical principles, the empirical data on
the doses at which adverse effects can be observed, and an appro-
priate degree of conservatism (Borgert et al., 2012; Caldwell et al.,
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